Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Asset Writedowns and Impairment (2023 - 2025)

Metagenomi (MGX) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $181000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 34.18% to $181000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $933000.0, a 206.91% increase, with the full-year FY2024 number at $1.0 million, up 4430.43% from a year prior.
  • Asset Writedowns and Impairment was $181000.0 for Q2 2025 at Metagenomi, down from $752000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $752000.0 in Q4 2024 to a low of $4000.0 in Q1 2024.
  • A 3-year average of $206166.7 and a median of $97500.0 in 2023 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 5271.43% in 2024, then tumbled 34.18% in 2025.
  • Metagenomi's Asset Writedowns and Impairment stood at $14000.0 in 2023, then soared by 5271.43% to $752000.0 in 2024, then crashed by 75.93% to $181000.0 in 2025.
  • Per Business Quant, the three most recent readings for MGX's Asset Writedowns and Impairment are $181000.0 (Q2 2025), $752000.0 (Q4 2024), and $11000.0 (Q3 2024).